Postop Pain Management in Pituitary Tumour Patients
Recruiting now Phase 4 NCT06353529
Run by Hamilton Health Sciences Corporation · for 18 to 100 · All sexes
What this study is about
To assess the benefit of using an additional nerve block during minimally invasive pituitary surgery, to improve pain management after surgery. The medication (Bupivacaine) or a placebo (saline) will be injected during surgery and patients will be asked about their level of pain at multiple time points in the first 24 hours following surgery. Some patients will be randomized to a third, sham group that do not receive any additional injection. The aim is to improve patient outcomes and reduce the need for pain medication after surgery.
Who can join (things the study team will check)
✅ You may be able to join if…
- adult patients (18 yrs or older)
- undergoing endonasal pituitary adenoma resection
🚫 You may not be able to join if…
- Patients with pre-existing chronic pain conditions requiring antidepressants (serotonin reuptake inhibitors), benzodiazepines, gabapentin, or opioid drugs
- contraindications to the performance of SPGB such as known allergy to used medications
- chronic alcohol abuse
- uncontrolled systemic arterial hypertension
- severe kidney or liver diseases
- cardiomyopathies or sustained cardiac arrhythmias (permanent paroxystic atrial fibrillation or other sustained supraventricular rhythmic anomalies)
Where this trial is running
- Hamilton General Hospital, Hamilton, Ontario, Canada
Who to contact
Dr. Kesava Reddy, MD · 905-521-2100 · reddy@hhsc.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06353529.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.